Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

VERTEX PHARMACEUTICALS INC / MA

Form 4

August 14, 2015

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average burden hours per

OMB APPROVAL

response...

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

Form 5 obligations may continue. See Instruction

Check this box

if no longer

Section 16.

Form 4 or

subject to

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * **BOGER JOSHUA S**

2. Issuer Name and Ticker or Trading

Symbol

3. Date of Earliest Transaction

5. Relationship of Reporting Person(s) to Issuer

VERTEX PHARMACEUTICALS

(Check all applicable)

INC / MA [VRTX]

(Middle)

(Month/Day/Year) 08/12/2015

_X__ Director Officer (give title

10% Owner Other (specify

C/O VERTEX

(Last)

PHARMACEUTICALS INCORPORATED, 50 NORTHERN

(Street)

08/12/2015

(First)

AVENUE

Stock

4. If Amendment, Date Original

Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

Applicable Line)

X Form filed by One Reporting Person Form filed by More than One Reporting

D

134.54 352,684

(2)(4)

BOSTON, MA 02210

(City)	(State)	(Zip) Tabl	le I - Non-I	Derivative	Secur	ities Acqui	red, Disposed of,	or Beneficiall	y Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr. 8)	4. Securiti onr Disposo (Instr. 3, 4)	ed of (land 5) (A) or	D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/12/2015		Code V M	Amount 10,400	(D) A	Price \$ 35.64	355,684	D	
Common Stock	08/12/2015		S <u>(1)</u>	1,300	D	\$ 133.53 (2) (3)	354,384	D	
Common	00/12/2015		c (1)	1 700	D	\$ 124.54	252 694	D	

1,700

 $S^{(1)}$

Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

Common Stock	08/12/2015	S <u>(1)</u>	2,800	D	\$ 135.48 (2) (5)	349,884	D	
Common Stock	08/12/2015	S <u>(1)</u>	1,700	D	\$ 136.48 (2) (6)	348,184	D	
Common Stock	08/12/2015	S <u>(1)</u>	2,600	D	\$ 137.5 (2) (7)	345,584	D	
Common Stock	08/12/2015	S <u>(1)</u>	300	D	\$ 138.07 (2) (8)	345,284	D	
Common Stock						13,286	I	401(k)
Common Stock						122,700	I	Common Stock held in trust

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 35.64	08/12/2015		M	10,400	<u>(9)</u>	02/01/2016	Common Stock	10,400

Reporting Owners

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

Reporting Owners 2

Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

BOGER JOSHUA S
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE
BOSTON, MA 02210
X

Signatures

Omar White, Attorney-In-Fact

**Signature of Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.

Date

- Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- (3) Open market sales reported on this line occurred at a weighted average price of \$133.53 (range \$133.00 to \$133.85).
- (4) Open market sales reported on this line occurred at a weighted average price of \$134.54 (range \$134.00 to \$134.97).
- (5) Open market sales reported on this line occurred at a weighted average price of \$135.48 (range \$135.00 to \$135.86).
- (6) Open market sales reported on this line occurred at a weighted average price of \$136.48 (range \$136.02 to \$136.90).
- (7) Open market sales reported on this line occurred at a weighted average price of \$137.50 (range \$137.04 to \$137.85).
- (8) Open market sales reported on this line occurred at a weighted average price of \$138.07 (range \$138.05 to \$138.11).
- (9) Fully vested.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3